{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T01:45:11Z","timestamp":1784771111089,"version":"3.55.0"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T00:00:00Z","timestamp":1742342400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T00:00:00Z","timestamp":1742342400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Rheumatol"],"DOI":"10.1186\/s42358-025-00448-5","type":"journal-article","created":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T07:23:01Z","timestamp":1742368981000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Suppression of skin lesions and SLE nephritis by increasing Treg in MRL\/FASlpr mice by administration of bee venom Apitoxin\u00ae"],"prefix":"10.1186","volume":"65","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4569-1728","authenticated-orcid":false,"given":"Duk-Yeon","family":"Cho","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-4151-7809","authenticated-orcid":false,"given":"Young-Mo","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1971-9758","authenticated-orcid":false,"given":"SangHo","family":"Seol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,19]]},"reference":[{"key":"448_CR1","doi-asserted-by":"crossref","unstructured":"Ameer MA, Chaudhry H, Mushtaq J, Khan OS, Babar M, Hashim T, et al. An overview of systemic lupus erythematosus (SLE) pathogenesis, classification, and management. Cureus. 2022;14(10).","DOI":"10.7759\/cureus.30330"},{"issue":"1","key":"448_CR2","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1111\/j.1600-065X.1999.tb01310.x","volume":"169","author":"OT Chan","year":"1999","unstructured":"Chan OT, Madaio MR, Shlomchik MJ, Chan OI, Madaio MP. The central and multiple roles of B cells in lupus pathogenesis. Immunol Rev. 1999;169(1):107\u201321.","journal-title":"Immunol Rev"},{"issue":"7","key":"448_CR3","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1136\/jcp.56.7.481","volume":"56","author":"C Mok","year":"2003","unstructured":"Mok C, Lau C. Pathogenesis of systemic lupus erythematosus. J Clin Pathol. 2003;56(7):481\u201390.","journal-title":"J Clin Pathol"},{"issue":"7","key":"448_CR4","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1016\/j.molmed.2017.05.006","volume":"23","author":"VR Moulton","year":"2017","unstructured":"Moulton VR, Suarez-Fueyo A, Meidan E, Li H, Mizui M, Tsokos GC. Pathogenesis of human systemic lupus erythematosus: a cellular perspective. Trends Mol Med. 2017;23(7):615\u201335.","journal-title":"Trends Mol Med"},{"key":"448_CR5","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s12519-019-00229-3","volume":"16","author":"L Pan","year":"2020","unstructured":"Pan L, Lu M-P, Wang J-H, Xu M, Yang S-R. Immunological pathogenesis and treatment of systemic lupus erythematosus. World J Pediatr. 2020;16:19\u201330.","journal-title":"World J Pediatr"},{"issue":"10381","key":"448_CR6","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1016\/S0140-6736(22)02607-1","volume":"401","author":"EF Morand","year":"2023","unstructured":"Morand EF, Vital EM, Petri M, van Vollenhoven R, Wallace DJ, Mosca M, et al. Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-I). Lancet. 2023;401(10381):1001\u201310.","journal-title":"Lancet"},{"issue":"3","key":"448_CR7","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1038\/s41584-021-00739-3","volume":"18","author":"AR Parra S\u00e1nchez","year":"2022","unstructured":"Parra S\u00e1nchez AR, Voskuyl AE, van Vollenhoven RF. Treat-to-target in systemic lupus erythematosus: advancing towards its implementation. Nat Rev Rheumatol. 2022;18(3):146\u201357.","journal-title":"Nat Rev Rheumatol"},{"issue":"2","key":"448_CR8","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1007\/s12016-017-8605-8","volume":"53","author":"A De Groof","year":"2017","unstructured":"De Groof A, H\u00e9mon P, Mignen O, Pers J-O, Wakeland EK, Renaudineau Y, et al. Dysregulated lymphoid cell populations in mouse models of systemic lupus erythematosus. Clin Rev Allergy Immunol. 2017;53(2):181\u201397.","journal-title":"Clin Rev Allergy Immunol"},{"issue":"2","key":"448_CR9","first-page":"69","volume":"1","author":"M Ali","year":"2012","unstructured":"Ali M. Studies on bee venom and its medical uses. Int J Adv Res Technol. 2012;1(2):69\u201383.","journal-title":"Int J Adv Res Technol"},{"key":"448_CR10","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1007\/s12016-017-8597-4","volume":"54","author":"D Elieh Ali Komi","year":"2018","unstructured":"Elieh Ali Komi D, Shafaghat F, Zwiener RD. Immunology of bee venom. Clin Rev Allergy Immunol. 2018;54:386\u201396.","journal-title":"Clin Rev Allergy Immunol"},{"key":"448_CR11","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1007\/s10555-011-9339-3","volume":"31","author":"N Or\u0161oli\u0107","year":"2012","unstructured":"Or\u0161oli\u0107 N. Bee venom in cancer therapy. Cancer Metastasis Rev. 2012;31:173\u201394.","journal-title":"Cancer Metastasis Rev"},{"issue":"16","key":"448_CR12","doi-asserted-by":"publisher","first-page":"2997","DOI":"10.3390\/molecules24162997","volume":"24","author":"R Wehbe","year":"2019","unstructured":"Wehbe R, Frangieh J, Rima M, El Obeid D, Sabatier J-M, Fajloun Z. Bee venom: Overview of main compounds and bioactivities for therapeutic interests. Molecules. 2019;24(16):2997.","journal-title":"Molecules"},{"issue":"1","key":"448_CR13","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.taap.2011.10.009","volume":"258","author":"M Jo","year":"2012","unstructured":"Jo M, Park MH, Kollipara PS, An BJ, Song HS, Han SB, et al. Anti-cancer effect of bee venom toxin and melittin in ovarian cancer cells through induction of death receptors and inhibition of JAK2\/STAT3 pathway. Toxicol Appl Pharmcol. 2012;258(1):72\u201381.","journal-title":"Toxicol Appl Pharmcol"},{"key":"448_CR14","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1007\/s00280-016-3160-1","volume":"78","author":"C-c Liu","year":"2016","unstructured":"Liu C-c, Hao D-j, Zhang Q, An J, Zhao J-j, Chen B, et al. Application of bee venom and its main constituent melittin for cancer treatment. Cancer Chemother Pharmacol. 2016;78:1113\u201330.","journal-title":"Cancer Chemother Pharmacol"},{"key":"448_CR15","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.canlet.2017.05.010","volume":"402","author":"I Rady","year":"2017","unstructured":"Rady I, Siddiqui IA, Rady M, Mukhtar H. Melittin, a major peptide component of bee venom, and its conjugates in cancer therapy. Cancer Lett. 2017;402:16\u201331.","journal-title":"Cancer Lett"},{"issue":"5","key":"448_CR16","doi-asserted-by":"publisher","first-page":"616","DOI":"10.3390\/molecules21050616","volume":"21","author":"G Lee","year":"2016","unstructured":"Lee G, Bae H. Anti-inflammatory applications of melittin, a major component of bee venom: Detailed mechanism of action and adverse effects. Molecules. 2016;21(5):616.","journal-title":"Molecules"},{"issue":"2","key":"448_CR17","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.bcp.2006.09.023","volume":"73","author":"HJ Park","year":"2007","unstructured":"Park HJ, Son DJ, Lee CW, Choi MS, Lee US, Song HS, et al. Melittin inhibits inflammatory target gene expression and mediator generation via interaction with I\u03baB kinase. Biochem Pharmacol. 2007;73(2):237\u201347.","journal-title":"Biochem Pharmacol"},{"key":"448_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1476-9255-5-7","volume":"5","author":"HJ Park","year":"2008","unstructured":"Park HJ, Lee HJ, Choi MS, Son DJ, Song HS, Song MJ, et al. JNK pathway is involved in the inhibition of inflammatory target gene expression and NF-kappaB activation by melittin. J Inflamm. 2008;5:1\u201313.","journal-title":"J Inflamm"},{"issue":"8","key":"448_CR19","doi-asserted-by":"publisher","first-page":"734","DOI":"10.2174\/1389201021666191210110826","volume":"21","author":"S-d He","year":"2020","unstructured":"He S-d, Tan N, Sun C-x, Liao K-h, Zhu H-j, Luo X-g, et al. Treatment with melittin induces apoptosis and autophagy of fibroblast-like synoviocytes in patients with rheumatoid arthritis. Curr Pharm Biotechnol. 2020;21(8):734\u201340.","journal-title":"Curr Pharm Biotechnol"},{"issue":"5","key":"448_CR20","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1016\/j.jbspin.2011.01.004","volume":"78","author":"S-K Kim","year":"2011","unstructured":"Kim S-K, Park K-Y, Yoon W-C, Park S-H, Park K-K, Yoo D-H, et al. Melittin enhances apoptosis through suppression of IL-6\/sIL-6R complex-induced NF-\u03baB and STAT3 activation and Bcl-2 expression for human fibroblast-like synoviocytes in rheumatoid arthritis. Joint Bone Spine. 2011;78(5):471\u20137.","journal-title":"Joint Bone Spine"},{"issue":"1","key":"448_CR21","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1254\/jphs.SC0070215","volume":"106","author":"S-S Nah","year":"2008","unstructured":"Nah S-S, Ha E, Mun SH, Won H-J, Chung J-H. Effects of melittin on the production of matrix metalloproteinase-1 and-3 in rheumatoid arthritic fibroblast-like synoviocytes. J Pharmacol Sci. 2008;106(1):162\u20136.","journal-title":"J Pharmacol Sci"},{"issue":"3","key":"448_CR22","doi-asserted-by":"publisher","first-page":"707","DOI":"10.3181\/00379727-127-32779","volume":"127","author":"JF Fennell","year":"1968","unstructured":"Fennell JF, Shipman WH, Cole LJ. Antibacterial action of melittin, a polypeptide from bee venom. Proc Soc Exp Biol Med. 1968;127(3):707\u201310.","journal-title":"Proc Soc Exp Biol Med"},{"issue":"3","key":"448_CR23","doi-asserted-by":"publisher","first-page":"198","DOI":"10.3390\/toxins12030198","volume":"12","author":"H Baek","year":"2020","unstructured":"Baek H, Park S-Y, Ku SJ, Ryu K, Kim Y, Bae H, et al. Bee venom phospholipase A2 induces regulatory T cell populations by suppressing apoptotic signaling pathway. Toxins. 2020;12(3):198.","journal-title":"Toxins"},{"issue":"1","key":"448_CR24","doi-asserted-by":"publisher","first-page":"3511","DOI":"10.1038\/s41598-021-82298-x","volume":"11","author":"G-M Choi","year":"2021","unstructured":"Choi G-M, Lee B, Hong R, Park S-Y, Cho D-E, Yeom M, et al. Bee venom phospholipase A2 alleviates collagen-induced polyarthritis by inducing Foxp3\u2009+\u2009regulatory T cell polarization in mice. Sci Rep. 2021;11(1):3511.","journal-title":"Sci Rep"},{"key":"448_CR25","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1007\/s13273-019-0034-8","volume":"15","author":"G Lee","year":"2019","unstructured":"Lee G, Kang G-H, Bae H. Bee venom phospholipase A2 suppression of experimental autoimmune encephalomyelitis is dependent on its enzymatic activity. Mol Cell Toxicol. 2019;15:307\u201313.","journal-title":"Mol Cell Toxicol"},{"issue":"2","key":"448_CR26","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/j.pharmthera.2007.04.004","volume":"115","author":"DJ Son","year":"2007","unstructured":"Son DJ, Lee JW, Lee YH, Song HS, Lee CK, Hong JT. Therapeutic application of anti-arthritis, pain-releasing, and anti-cancer effects of bee venom and its constituent compounds. Pharmacol Ther. 2007;115(2):246\u201370.","journal-title":"Pharmacol Ther"},{"issue":"1","key":"448_CR27","doi-asserted-by":"publisher","first-page":"655","DOI":"10.4049\/jimmunol.179.1.655","volume":"179","author":"KM Stuhlmeier","year":"2007","unstructured":"Stuhlmeier KM. Apis mellifera venom and melittin block neither NF-\u03baB-p50-DNA interactions nor the activation of NF-\u03baB, instead they activate the transcription of proinflammatory genes and the release of reactive oxygen intermediates. J Immunol. 2007;179(1):655\u201364.","journal-title":"J Immunol"},{"issue":"02","key":"448_CR28","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1142\/S0192415X01000228","volume":"29","author":"Y-B Kwon","year":"2001","unstructured":"Kwon Y-B, Kim J-H, Yoon J-H, Lee J-D, Han H-J, Mar W-C, et al. The analgesic efficacy of bee venom acupuncture for knee osteoarthritis: a comparative study with needle acupuncture. Am J Chin Med. 2001;29(02):187\u201399.","journal-title":"Am J Chin Med"},{"issue":"1","key":"448_CR29","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/j.cyto.2012.10.005","volume":"61","author":"MS Choi","year":"2013","unstructured":"Choi MS, Park S, Choi T, Lee G, Haam K-K, Hong M-C, et al. Bee venom ameliorates ovalbumin induced allergic asthma via modulating CD4\u2009+\u2009CD25\u2009+\u2009regulatory T cells in mice. Cytokine. 2013;61(1):256\u201365.","journal-title":"Cytokine"},{"issue":"19","key":"448_CR30","doi-asserted-by":"publisher","first-page":"7015","DOI":"10.3390\/ijms21197015","volume":"21","author":"PJ Eggenhuizen","year":"2020","unstructured":"Eggenhuizen PJ, Ng BH, Ooi JD. Treg enhancing therapies to treat autoimmune diseases. Int J Mol Sci. 2020;21(19):7015.","journal-title":"Int J Mol Sci"},{"key":"448_CR31","doi-asserted-by":"publisher","first-page":"102376","DOI":"10.1016\/j.jaut.2019.102376","volume":"110","author":"C Scheinecker","year":"2020","unstructured":"Scheinecker C, G\u00f6schl L, Bonelli M. Treg cells in health and autoimmune diseases: new insights from single cell analysis. J Autoimmun. 2020;110:102376.","journal-title":"J Autoimmun"},{"key":"448_CR32","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.coi.2015.09.002","volume":"37","author":"A Spence","year":"2015","unstructured":"Spence A, Klementowicz JE, Bluestone JA, Tang Q. Targeting Treg signaling for the treatment of autoimmune diseases. Curr Opin Immunol. 2015;37:11\u201320.","journal-title":"Curr Opin Immunol"},{"issue":"1","key":"448_CR33","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1111\/j.0105-2896.2005.00247.x","volume":"204","author":"S Paust","year":"2005","unstructured":"Paust S, Cantor H. Regulatory T cells and autoimmune disease. Immunol Rev. 2005;204(1):195\u2013207.","journal-title":"Immunol Rev"},{"issue":"5","key":"448_CR34","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1002\/art.10558","volume":"47","author":"AF Kavanaugh","year":"2002","unstructured":"Kavanaugh AF, Solomon DH, Guidelines ACoRAHCoIT. Guidelines for immunologic laboratory testing in the rheumatic diseases: Anti-DNA antibody tests. Arthritis Care Res. 2002;47(5):546\u201355.","journal-title":"Arthritis Care Res"},{"issue":"11","key":"448_CR35","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1002\/art.1780251101","volume":"25","author":"EM Tan","year":"1982","unstructured":"Tan EM, Cohen AS, Fries JF, Masi AT, Mcshane DJ, Rothfield NF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheumatism: Official J Am Coll Rheumatol. 1982;25(11):1271\u20137.","journal-title":"Arthritis Rheumatism: Official J Am Coll Rheumatol"},{"issue":"5","key":"448_CR36","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1191\/0961203303lu1015oa","volume":"13","author":"J Reveille","year":"2004","unstructured":"Reveille J. Predictive value of autoantibodies for activity of systemic lupus erythematosus. Lupus. 2004;13(5):290\u20137.","journal-title":"Lupus"},{"issue":"12","key":"448_CR37","first-page":"797","volume":"11","author":"D Isenberg","year":"2002","unstructured":"Isenberg D, Smeenk R. Clinical laboratory assays for measuring anti-dsDNA antibodies. Where are we now? Lupus. 2002;11(12):797\u2013800.","journal-title":"Where Are We Now?? Lupus"},{"key":"448_CR38","first-page":"S20","volume":"15","author":"RA Sinico","year":"2002","unstructured":"Sinico RA, Bollini B, Sabadini E, Di Toma L, Radice A. The use of laboratory tests in diagnosis and monitoring of systemic lupus erythematosus. J Nephrol. 2002;15:S20\u20137.","journal-title":"J Nephrol"},{"issue":"1","key":"448_CR39","doi-asserted-by":"publisher","first-page":"2035117","DOI":"10.1080\/21645515.2022.2035117","volume":"18","author":"TK Goswami","year":"2022","unstructured":"Goswami TK, Singh M, Dhawan M, Mitra S, Emran TB, Rabaan AA, et al. Regulatory T cells (Tregs) and their therapeutic potential against autoimmune disorders\u2013Advances and challenges. Hum Vaccines Immunotherapeutics. 2022;18(1):2035117.","journal-title":"Hum Vaccines Immunotherapeutics"},{"key":"448_CR40","doi-asserted-by":"publisher","first-page":"973813","DOI":"10.3389\/fimmu.2022.973813","volume":"13","author":"J Schl\u00f6der","year":"2022","unstructured":"Schl\u00f6der J, Shahneh F, Schneider F-J, Wieschendorf B. Boosting regulatory T cell function for the treatment of autoimmune diseases\u2013That\u2019s only half the battle! Front Immunol. 2022;13:973813.","journal-title":"Front Immunol"},{"issue":"16","key":"448_CR41","doi-asserted-by":"publisher","first-page":"8371","DOI":"10.3390\/ijms22168371","volume":"22","author":"M Burzy\u0144ska","year":"2021","unstructured":"Burzy\u0144ska M, Piasecka-Kwiatkowska D. A review of honeybee venom allergens and allergenicity. Int J Mol Sci. 2021;22(16):8371.","journal-title":"Int J Mol Sci"},{"key":"448_CR42","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13049-016-0344-y","volume":"25","author":"A Ruiz Oropeza","year":"2017","unstructured":"Ruiz Oropeza A, Mikkelsen S, Bindslev-Jensen C, Mortz CG. Pre-hospital treatment of bee and wasp induced anaphylactic reactions: a retrospective study. Scand J Trauma Resusc Emerg Med. 2017;25:1\u20138.","journal-title":"Scand J Trauma Resusc Emerg Med"},{"issue":"1","key":"448_CR43","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1093\/ecam\/neh070","volume":"2","author":"J-D Lee","year":"2005","unstructured":"Lee J-D, Park H-J, Chae Y, Lim S. An overview of bee venom acupuncture in the treatment of arthritis. Evidence-Based Complement Altern Med. 2005;2(1):79\u201384.","journal-title":"Evidence-Based Complement Altern Med"},{"key":"448_CR44","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.toxicon.2018.04.012","volume":"148","author":"S Zhang","year":"2018","unstructured":"Zhang S, Liu Y, Ye Y, Wang X-R, Lin L-T, Xiao L-Y, et al. Bee venom therapy: potential mechanisms and therapeutic applications. Toxicon. 2018;148:64\u201373.","journal-title":"Toxicon"},{"issue":"2","key":"448_CR45","doi-asserted-by":"publisher","first-page":"66","DOI":"10.3390\/toxins12020066","volume":"12","author":"A Aufschnaiter","year":"2020","unstructured":"Aufschnaiter A, Kohler V, Khalifa S, Abd El-Wahed A, Du M, El-Seedi H, et al. Apitoxin and its components against cancer, neurodegeneration and rheumatoid arthritis: Limitations and possibilities. Toxins. 2020;12(2):66.","journal-title":"Toxins"},{"issue":"12","key":"448_CR46","doi-asserted-by":"publisher","first-page":"2890","DOI":"10.3390\/toxins2122890","volume":"2","author":"F Pavone","year":"2010","unstructured":"Pavone F, Luvisetto S. Botulinum neurotoxin for pain management: insights from animal models. Toxins. 2010;2(12):2890\u2013913.","journal-title":"Toxins"},{"issue":"12","key":"448_CR47","doi-asserted-by":"publisher","first-page":"691","DOI":"10.3390\/toxins15120691","volume":"15","author":"S Hwang","year":"2023","unstructured":"Hwang S, Seo M, Lee TH, Lee HJ, Park J-w, Kwon BS, et al. Comparison of the effects of botulinum toxin doses on nerve regeneration in rats with experimentally induced sciatic nerve injury. Toxins. 2023;15(12):691.","journal-title":"Toxins"},{"issue":"11","key":"448_CR48","doi-asserted-by":"publisher","first-page":"3360","DOI":"10.3390\/nu12113360","volume":"12","author":"M Carpena","year":"2020","unstructured":"Carpena M, Nu\u00f1ez-Estevez B, Soria-Lopez A, Simal-Gandara J. Bee venom: an updating review of its bioactive molecules and its health applications. Nutrients. 2020;12(11):3360.","journal-title":"Nutrients"},{"key":"448_CR49","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.3389\/fimmu.2018.01457","volume":"9","author":"X Fang","year":"2018","unstructured":"Fang X, Zaman MH, Guo X, Ding H, Xie C, Zhang X, et al. Role of hepatic deposited immunoglobulin G in the pathogenesis of liver damage in systemic lupus erythematosus. Front Immunol. 2018;9:1457.","journal-title":"Front Immunol"},{"issue":"4","key":"448_CR50","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1111\/imm.12908","volume":"154","author":"X Guo","year":"2018","unstructured":"Guo X, Fang X, He G, Zaman MH, Fei X, Qiao W, et al. The role of neutrophils in skin damage induced by tissue-deposited lupus IgG. Immunology. 2018;154(4):604\u201312.","journal-title":"Immunology"},{"issue":"12","key":"448_CR51","doi-asserted-by":"publisher","first-page":"7154","DOI":"10.4049\/jimmunol.0902514","volume":"184","author":"G-M Deng","year":"2010","unstructured":"Deng G-M, Liu L, Kyttaris VC, Tsokos GC. Lupus serum IgG induces skin inflammation through the TNFR1 signaling pathway. J Immunol. 2010;184(12):7154\u201361.","journal-title":"J Immunol"},{"key":"448_CR52","doi-asserted-by":"publisher","first-page":"3020","DOI":"10.3389\/fimmu.2019.03020","volume":"10","author":"Q Zhang","year":"2020","unstructured":"Zhang Q, Xiang L, Zaman MH, Dong W, He G, Deng G-M. Predominant role of immunoglobulin G in the pathogenesis of splenomegaly in murine lupus. Front Immunol. 2020;10:3020.","journal-title":"Front Immunol"},{"issue":"2","key":"448_CR53","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1111\/j.1523-1755.2004.00443.x","volume":"65","author":"JJ Weening","year":"2004","unstructured":"Weening JJ, D\u2019agati VD, Schwartz MM, Seshan SV, Alpers CE, Appel GB, et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited. Kidney Int. 2004;65(2):521\u201330.","journal-title":"Kidney Int"},{"issue":"7","key":"448_CR54","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1038\/s41577-022-00816-y","volume":"23","author":"H-J Anders","year":"2023","unstructured":"Anders H-J, Kitching AR, Leung N, Romagnani P. Glomerulonephritis: Immunopathogenesis and immunotherapy. Nat Rev Immunol. 2023;23(7):453\u201371.","journal-title":"Nat Rev Immunol"},{"issue":"12","key":"448_CR55","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1056\/NEJMoa2001180","volume":"383","author":"R Furie","year":"2020","unstructured":"Furie R, Rovin BH, Houssiau F, Malvar A, Teng YO, Contreras G, et al. Two-year, randomized, controlled trial of belimumab in lupus nephritis. N Engl J Med. 2020;383(12):1117\u201328.","journal-title":"N Engl J Med"},{"issue":"1","key":"448_CR56","doi-asserted-by":"publisher","first-page":"84","DOI":"10.3109\/08916930903374600","volume":"43","author":"N Jacob","year":"2010","unstructured":"Jacob N, Stohl W. Autoantibody-dependent and autoantibody-independent roles for B cells in systemic lupus erythematosus: past, present, and future. Autoimmunity. 2010;43(1):84\u201397.","journal-title":"Autoimmunity"},{"issue":"4","key":"448_CR57","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1136\/ard.2005.044974","volume":"65","author":"S Mellor-Pita","year":"2006","unstructured":"Mellor-Pita S, Citores M, Castejon R, Tutor-Ureta P, Yebra-Bango M, Andreu J, et al. Decrease of regulatory T cells in patients with systemic lupus erythematosus. Ann Rheum Dis. 2006;65(4):553\u20134.","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"448_CR58","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.cyto.2014.12.027","volume":"72","author":"RM Talaat","year":"2015","unstructured":"Talaat RM, Mohamed SF, Bassyouni IH, Raouf AA. Th1\/Th2\/Th17\/Treg cytokine imbalance in systemic lupus erythematosus (SLE) patients: correlation with disease activity. Cytokine. 2015;72(2):146\u201353.","journal-title":"Cytokine"},{"issue":"3","key":"448_CR59","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1056\/NEJMoa1912196","volume":"382","author":"EF Morand","year":"2020","unstructured":"Morand EF, Furie R, Tanaka Y, Bruce IN, Askanase AD, Richez C, et al. Trial of anifrolumab in active systemic lupus erythematosus. N Engl J Med. 2020;382(3):211\u201321.","journal-title":"N Engl J Med"},{"issue":"9767","key":"448_CR60","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1016\/S0140-6736(10)61354-2","volume":"377","author":"SV Navarra","year":"2011","unstructured":"Navarra SV, Guzm\u00e1n RM, Gallacher AE, Hall S, Levy RA, Jimenez RE, et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet. 2011;377(9767):721\u201331.","journal-title":"Lancet"}],"container-title":["Advances in Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s42358-025-00448-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s42358-025-00448-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s42358-025-00448-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T10:02:24Z","timestamp":1763373744000},"score":1,"resource":{"primary":{"URL":"https:\/\/advancesinrheumatology.biomedcentral.com\/articles\/10.1186\/s42358-025-00448-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,19]]},"references-count":60,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["448"],"URL":"https:\/\/doi.org\/10.1186\/s42358-025-00448-5","relation":{},"ISSN":["2523-3106"],"issn-type":[{"value":"2523-3106","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,19]]},"assertion":[{"value":"31 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Animal experiments were approved and performed in accordance with the approved guidelines of the Institutional Animal Care and Use Committee of Kyungpook National University, Republic of Korea (2024\u2009\u2212\u20090229).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Clinical trial number"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"17"}}